10th Annual Oncology Innovation Forum 2024 | Sachs Associates Ltd | 31 May 2024 | Waldorf Astoria Chicago Hotel, 11 E Walton St, Chicago, IL 60611, USA

This event is an established networking opportunity for senior biotech executives to meet Pharma Licensing teams and financial and corporate investors and their advisers. Meetings take place alongside a stimulating program focusing on the latest trends in pharma-biotech dealmaking, the latest innovation in IO targets and modalities. There is also an ASCO forecast panel with industry analysts sharing their views on what to expect. This will be available on demand for the virtual audience the week after ASCO. Additionally, there will be pre-arranged in-person and virtual meetings, live and on-demand company showcases, and a reception.

The event brings together leaders from cancer research institutes, patient advocacy groups, pharma, biotech, and Wall Street, to facilitate partnering, funding and investment. We anticipate around 250 delegates and 20+ company presentations by established and emerging companies with part of the audience participating virtually. This will include a limited number of live presentations taking place in dedicated presentation tracks, alongside virtual company showcases, which will be available on demand. Recorded sessions will also be added on demand on the event’s portal during the virtual week.

The programme will consist of:
• BioPharma Dealmakers Roundtable
• New Endpoints for Early-Stage Oncology Companies Panel
• Investing in NextGen ADCs Panel
• Biotech Innovation in Cellular & Genetic Immunotherapies Panel
• New Methods of Therapeutic Delivery for Oncology Panel
• New Hubs for Innovation Panel
• ASCO Forecast Discussion

2024 Speakers

SPEAKERS & CHAIRS:

Brad Loncar
Founder, BiotechTV

Chris Sheldon
SVP, Head of Business Development, GSK

David Benathan
VP, BD&L Partnering Head Oncology, Novartis AG

Devang Bhuva
SVP, Corporate Development, Gilead Sciences, Inc.

Jacob Plieth
Senior Journalist, ApexOnco

James Mulé
Associate Center Director for
Translational Research, Moffitt Cancer Center Foundation

Jay Olson
Managing Director & Senior Analyst, Oppenheimer & Co. Inc.

Jeffrey Bockman
EVP, BioConsulting, Head of Oncology, Lumanity

John DeYoung
VP, Worldwide Business Development, Pfizer, Inc.

Kaveri Pohlman
Director, Biotechnology Equity Research, BTIG, LLC

Michael Kingston
Managing Director & Head of North America Life Sciences, Lazard Ltd.

Michael Rice
Expert Advisor, SVP, Cell & Gene Therapy, Lumanity

Michael Salgaller
Supervisor Specialist, National Institutes of Health (NIH)

Michal Preminger
Head, Johnson & Johnson Innovation, East North America, Johnson & Johnson Innovation LLC

Nadim Ahmed
President & CEO, Cullinan Oncology, LLC

Niels Emmerich
VP, Global Head Search & Evaluation, AbbVie, Inc.

Paul Rennert
CEO, Aleta Biotherapeutics

Peter Sandor
SVP, PFL Oncology, Astellas Pharma, Inc.

Sam Fazeli
Head of Research, Senior Pharmaceuticals Analyst, Bloomberg Intelligence

Vivek Abraham
Director, Oncology Search & Evaluation, AbbVie, Inc.